Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai to Set Up Research Base in Yokohama, Shutter 2 Labs
May 22, 2019
- Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
- 1st Oral Proceedings Held for Bayer Employee Damage Suit
May 21, 2019
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- Daiichi Sankyo Returns Part of Govt Grant for H5N1 Influenza Vaccine Project after Missing Supply Target
May 21, 2019
- Taisho Completes Tender Offer for Vietnamese Drug Maker
May 21, 2019
- Reducing Production Cost of Stemirac Is Key Issue: Nipro Pres.
May 20, 2019
- Top 4 Wholesalers See Over 1% Operating Margins in FY2018, Thanks Partly to Distribution Improvement Guidelines
May 20, 2019
- Ribomic Confident in Efficacy Outcome of Upcoming PII of Wet-AMD Treatment with Just 40 Patients: Pres.
May 20, 2019
- Fuji Pharma to File Biosimilars for Japan Approval by 2021: President
May 20, 2019
- JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman
May 20, 2019
- Ohara Join Hands with Nigerian Pharma, Eying Future Population Growth in Africa
May 17, 2019
- Suzuken to Exclusively Distribute Kymriah in Japan
May 17, 2019
- 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
- Daiichi Sankyo’s Quizartinib Voted Down by US FDA Advisory Committee
May 16, 2019
- Yutaka Ogihara, Grandson of Founder Hiroshi Ogihara, to Lead Kyorin Holdings
May 16, 2019
- Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
May 15, 2019
- Nichi-Iko Aims at Overseas Sales of 60 Billion Yen in FY2021; Infliximab Biosimilar in the US to Play Key Role
May 15, 2019
- AnGes Delays Launch of Collategene, “Sale Preparations Will Take More Time”
May 15, 2019
- Nichi-Iko Reduces Its Stake in Aprogen, Biz Tie-Up to Stay
May 14, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…